今天，我们来看一则新闻，诺华制药拒绝免费捐赠流感疫苗，同时也来锻炼下您的英语，让我们在娱乐中思考！在一点一滴中进步！
全球最大制药商之一、瑞士诺华制药(Novartis)的首席执行官魏思乐(Daniel Vasella)表示，诺华不可能向穷人捐赠疫苗，以保护他们预防最新的流感疫情。他表示，发展中国家或捐赠国应承担这笔开支。
The head of one of the world's largest pharmaceutical companies has ruled out donations of vaccines to protect the poor against the latest flu pandemic, saying that developing countries or donor nations should cover the costs.
魏思乐告诉英国《金融时报》，他将考虑以折扣价向低收入国家提供流感疫苗，但同时称：“如果你希望生产可以持续下去，你必须提供物质激励。”
Daniel Vasella, chief executive of Novartis, based in Switzerland, told the FT he would consider offering discounted pricing on flu vaccines to low-income nations, but said: “If you want to make production sustainable, you have to create financial incentives.”
他的这番话是对世界卫生组织(WHO)总干事陈冯富珍(Margaret Chan)的回绝。WHO发表声明称，甲型H1N1猪流感疫情目前已发展成世界性流行病。陈冯富珍呼吁疫苗生产商“团结”起来，为穷人提供疫苗。
His comments were a rebuff to Margaret Chan, director-general of the World Health Organisation, which has declared that the H1N1 swine flu outbreak is now a pandemic. She has called on vaccine makers to show “solidarity” in offering vaccines to the poor
魏思乐的言论突显出制药业内部的分歧。葛兰素史克(GlaxoSmithKline)许诺，将为穷人提供5000万支疫苗，一些发展中国家的小型制药商也表示，将专门拨出产量的10%，用于免费发放。
The remarks highlight divisions within the pharmaceutical industry, with GlaxoSmithKline saying it will pledge 50m doses for the poor, and some smaller producers in developing countries saying they will earmark 10 per cent of their production for free distribution.
诺华旗下的美国疫苗生产商Chiron上周五称，自己是首家完成试验性H1N1疫苗生产的制药商。该公司使用的是一种加速的细胞技术，而非传统的蛋坯制法。与此同时，其竞争对手也纷纷发表声明，表明各自的进展情况。澳大利亚的CSL公司称，将于8月中旬生产出首批疫苗。
Novartis owns Chiron, the US-based vaccine company which on Friday claimed it was the first producer to complete trial H1N1 vaccine batches using an accelerated cell-based technique rather than conventional production in eggs. Its announcement came as rival manufacturers issued statements staking out their positions, with CSL of Australia claiming it would have batches ready by mid-August.
葛兰素史克、赛诺菲－安万特(Sanofi-Aventis)、阿斯利康(AstraZeneca)旗下的MedImmune、以及百特(Baxter)也参与了竞争，其中一些证实，已收到订单，最早一批疫苗将于9月或10月前面世。
GSK, Sanofi-Aventis, MedImmune (part of AstraZeneca) and Baxter are all also in the race, with some confirming orders have been placed and early stocks should be ready by September or October.
魏思乐还警告称，诺华的H1N1疫苗供应中，“很大”一部分已被各国政府预定，这加大了供应短缺的可能性，就连那些能负担得起疫苗的富裕国家也无法幸免。他预计，每支疫苗售价将在10美元至15美元之间。
Mr Vasella also warned that a “significant” proportion of Novartis's H1N1 stock had already been reserved by governments, raising the prospect of shortages even among richer nations that can afford to purchase vaccines. He estimated the cost would be $10-$15 a dose
